Literature DB >> 8303732

Hemostatic markers in acute transient ischemic attacks.

E A Fon1, A Mackey, R Côté, C Wolfson, D M McIlraith, J Leclerc, F Bourque.   

Abstract

BACKGROUND AND
PURPOSE: Hemostatic abnormalities have been shown previously in stroke patients. The purpose of this study was to assess the activity of selected parameters of the coagulation system in acute reversible cerebral ischemia.
METHODS: We measured fibrinopeptide A, thrombin-antithrombin III, and D-dimer in 36 patients in both the acute (< 7 days) and postacute stage (1 and 3 months) after a transient ischemic attack (TIA). The results were compared with those of 20 asymptomatic patients with a history of remote TIA and 65 age- and sex-matched controls.
RESULTS: Mean fibrinopeptide A and thrombin-antithrombin III values were elevated in the acute stage after a TIA (P < .02) compared with levels at 1 month. In contrast, D-dimer was significantly increased at all three times points after the event when compared with remote TIA (P < .05) or control subjects (P < .001). No association could be found between marker levels and clinical outcome or the degree of cervical atherosclerosis as assessed by duplex ultrasonography.
CONCLUSIONS: These findings suggest that after acute reversible cerebral ischemia, there is early transient activation of thrombogenesis and ongoing fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8303732     DOI: 10.1161/01.str.25.2.282

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

Review 1.  Blood biomarkers of ischemic stroke.

Authors:  Glen C Jickling; Frank R Sharp
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

2.  Identification of circulating microRNAs as potential biomarkers for detecting acute ischemic stroke.

Authors:  Pengfei Li; Fengmeng Teng; Feng Gao; Mingshun Zhang; Jinping Wu; Chunbing Zhang
Journal:  Cell Mol Neurobiol       Date:  2014-11-20       Impact factor: 5.046

3.  Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

4.  Candidate Biomarkers for the Diagnosis of Transient Ischemic Attack: A Systematic Review.

Authors:  L Servaas Dolmans; Frans H Rutten; Niels C T Koenen; Marie-Louise E L Bartelink; Johannes B Reitsma; L Jaap Kappelle; Arno W Hoes
Journal:  Cerebrovasc Dis       Date:  2019-08-30       Impact factor: 2.762

5.  Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events.

Authors:  Matthew Gissel; Anetta Undas; Agnieszka Slowik; Kenneth G Mann; Kathleen E Brummel-Ziedins
Journal:  Thromb Res       Date:  2010-08-14       Impact factor: 3.944

6.  Transient ischemic attacks characterized by RNA profiles in blood.

Authors:  X Zhan; G C Jickling; Y Tian; B Stamova; H Xu; B P Ander; R J Turner; M Mesias; P Verro; C Bushnell; S C Johnston; F R Sharp
Journal:  Neurology       Date:  2011-10-12       Impact factor: 9.910

Review 7.  The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack.

Authors:  Matthew B Jensen; Marcus R Chacon; Justin A Sattin; Aitziber Aleu; Patrick D Lyden
Journal:  Neurologist       Date:  2008-07       Impact factor: 1.398

8.  Molecular biomarkers in stroke diagnosis and prognosis.

Authors:  Matthew B Maas; Karen L Furie
Journal:  Biomark Med       Date:  2009-08-01       Impact factor: 2.851

9.  Thrombin antithrombin complex and IL-18 serum levels in stroke patients.

Authors:  Ornella Piazza; Giuliana Scarpati; Simona Cotena; Maria Lonardo; Rosalba Tufano
Journal:  Neurol Int       Date:  2010-06-21

Review 10.  Biomarkers for Transient Ischemic Attack: A Brief Perspective of Current Reports and Future Horizons.

Authors:  Masoud Nouri-Vaskeh; Neda Khalili; Alireza Sadighi; Yalda Yazdani; Ramin Zand
Journal:  J Clin Med       Date:  2022-02-17       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.